Foregoing surgery is feasible after successful immunotherapy


Immunotherapy prior to surgery (neoadjuvant immunotherapy) has once again proven its efficacy in melanoma patients with lymph node metastases (stage 3 melanoma), as shown by the PRADO study, published on June 5.

This phase II study, led by Christian Blank of the Netherlands Cancer Institute and Leiden University Medical Center, confirmed the efficacy of a combination therapy involving the checkpoint inhibitors ipilimumab and nivolumab in a neoadjuvant setting. The PRADO study also showed that extensive surgery can be omitted in patients who respond very well to the therapy, which can increase the patients' quality of life. There are even benefits for patients showing a poor response and who generally face a poor prognosis: postoperative treatment appears to improve recurrence-free survival rates in this patient group as well.

Publication in Nature Medicine, June 5, 2022.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.